FGFR信号传导通路在特发性肺纤维化和非小细胞肺癌发病中作用机制的研究进展

doi:10.13481/j.1671-587x.20160640

[1] Vancheri C. Common pathways in idiopathic pulmonary fibrosis and cancer[J].Eur Respir Rev,2013,22(129):265-272.
[2] Tomassetti S,Gurioli C,Ryu JH,et al.The impact of lung cancer on survival of idiopathic pulmonary fibrosis[J].Chest,2015,147(1):157-164.
[3] Grimminger F,Schermuly RT,Ghofrani HA.Targeting non-malignant disorders with tyrosine kinase inhibitors[J].Nat Rev Drug Discov,2010,9(12):956-970.
[4] Beyer C,Distler JH.Tyrosine kinase signaling in fibrotic disorders:translation of basic research to human disease[J].Biochim Biophys Acta,2013,1832(7):897-904.
[5] Turner N,Grose R.Fibroblast growth factor signalling:from development to cancer[J].Nat Rev Cancer,2010,10(2):116-129.
[6] Wesche J,Haglund K,Haugsten EM.Fibroblast growth factors and their receptors in cancer[J].Biochem J,2011,437(2):199-213.
[7] Lieu C,Heymach J,Overman M,et al.Beyond VEGF:inhibition of the fibroblast growth factor pathway and antiangiogenesis[J].Clin Cancer Res,2011,17(19):6130-6139.
[8] Beenken A,Mohammadi M.The FGF family:biology,pathophysiology and therapy[J].Nat Rev Drug Discov,2009,8(3):235-253.
[9] Desai A,Adjei A.FGFR signaling as a target for lung cancer therapy[J].J Thorac Oncol,2016,11(1):9-20.
[10] Tiseo M,Gelsomino F,Alfieri R,et al.FGFR as potential target in the treatment of squamous non small cell lung cancer[J].Cancer Treat Rev,2015,41(6):527-539.
[11] Ahmad I,Iwata T,Leung HY.Mechanisms of FGFR-mediated carcinogenesis[J].Biochim Biophys Acta,2012,1823(4):850-860.
[12] Dutt A,Ramos AH,Hammerman PS,et al.Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer[J].PLoS One,2011,6(6):e20351.
[13] Wu YM,Su F,Kalyana-Sundaram S,et al.Identification of targetable FGFR gene fusions in diverse cancers[J].Cancer Discov,2013,3(6):636-647.
[14] Dienstmann R,Rodon J,Prat A,et al.Genomic aberrations in the FGFR pathway:opportunities for targeted therapies in solid tumors[J].Ann Oncol,2014,25(3):552-663.
[15] Marek L,Ware KE,Fritzsche A,et al.Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells[J].Mol Pharmacol,2009,75(1):196-207.
[16] Semrad TJ,Mack PC.Fibroblast growth factor signaling in non-small-cell lung cancer[J].Clin Lung Cancer,2012,13(2):90-95.
[17] Kim HR,Kim DJ,Kang DR,et al.Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer[J].J Clin Oncol,2013,31(6):731-737.
[18] Cihoric N,Savic S,Schneider S,et al.Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer[J].Br J Cancer,2014,110(12):2914-2922.
[19] Weiss J,Sos ML,Seidel D,et al.Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer[J].Sci Transl Med,2010,2(62):62ra93.
[20] Heist RS,Mino-Kenudson M,Sequist LV,et al.FGFR1 amplification in squamous cell carcinoma of the lung[J].J Thorac Oncol,2012,7(12):1775-1780.
[21] Craddock KJ,Ludkovski O,Sykes J,et al.Prognostic value of fibroblast growth factor receptor 1 gene locus amplification in resected lung squamous cell carcinoma[J].J Thorac Oncol,2013,8(11):1371-1377.
[22] 蒲丹,侯梅.成纤维生长因子受体非小细胞肺癌中的研究进展[J].中国肺癌杂志,2013,16(11):609-614.
[23] Greenman C,Stephens P,Smith R,et al.Patterns of somatic mutation in human cancer genomes[J].Nature,2007,446(7132):153-158.
[24] Liao RG,Jung J,Tchaicha J,et al.Inhibitor-sensitive FGFR2 and FGFR3 mutations in lung squamous cell carcinoma[J].Cancer Res,2013,73(16):5195-5205.
[25] Capelletti M,Dodge ME,Ercan D,et al.Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma[J].Clin Cancer Res,2014,20(24):6551-6558.
[26] Presta M,Dell'Era P,Mitola S,et al.Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis[J].Cytokine Growth Factor Rev,2005,16(2):159-178.
[27] Tchaicha JH,Akbay EA,Altabef A,et al.Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a pan-FGFR inhibitor in a mouse model of NSCLC[J].Cancer Res,2014,74(17):4676-4684.
[28] Hanumegowda C,Farkas L,Kolb M.Angiogenesis in pulmonary fibrosis:too much or not enough?[J].Chest,2012,142(1):200-207.
[29] Woodcock HV,Molyneaux PL,Maher TM.Reducing lung function decline in patients with idiopathic pulmonary fibrosis:potential of nintedanib[J].Drug Des Devel Ther,2013,7:503-510.
[30] MacKenzie B,Korfei M,Henneke I,et al.Increased FGF1-FGFRc expression in idiopathic pulmonary fibrosis[J].Respir Res,2015,16:83.
[31] Ramos C,Becerril C,Montano M,et al.FGF-1 reverts epithelial-mesenchymal transition induced by TGF-{beta}1 through MAPK/ERK kinase pathway[J].Am J Physiol Lung Cell Mol Physiol,2010,299(2):L222-231.
[32] Gupte VV,Ramasamy SK,Reddy R,et al.Overexpression of fibroblast growth factor-10 during both inflammatory and fibrotic phases attenuates bleomycin-induced pulmonary fibrosis in mice[J].Am J Respir Crit Care Med,2009,180(5):424-436.
[33] Ju W,Zhihong Y,Zhiyou Z,et al.Inhibition of α-SMA by the ectodomain of FGFR2c attenuates lung fibrosis[J].Mol Med,2012,18:992-1002.
[34] Yu ZH,Wang DD,Zhou ZY.Mutant soluble ectodomain of fibroblast growth factor receptor-2Ⅲc attenuates bleomycin-induced pulmonary fibrosis in mice[J].Biol Pharm Bull,2012,35(5):731-736.
[35] Joannes A,Brayer S,Besnard V,et al.FGF9 and FGF18 in idiopathic pulmonary fibrosis promote survival and migration and inhibit myofibroblast differentiation of human lung fibroblasts in vitro[J].Am J Physiol Lung Cell Mol Physiol,2016,310(7):L615-629.
[36] Richeldi L,Costabel U,Selman M,et al.Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis[J].N Engl J Med,2011,365(12):1079-1087.
[37] Ledermann JA,Hackshaw A,Kaye S,et al.Randomized phase Ⅱ placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer[J].J Clin Oncol,2011,29(28):3798-3804.
[38] Reck M,Kaiser R,Mellemgaard A,et al.Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1):a phase 3,double-blind,randomised controlled trial[J].Lancet Oncol,2014,15(2):143-155.
[39] Spagnolo P,Maher TM,Richeldi L.Idiopathic pulmonary fibrosis:Recent advances onpharmacological therapy[J].Pharmarcol Ther,2015,152:18-27.
[40] Kutluk Cenik B,Ostapoff KT,Gerber DE,et al.BIBF 1120(Nintedanib),a triple angiokinase inhibitor,induces hypoxia but not EMT and blocks progression of preclinical models of lung and pancreatic cancer[J].Mol Cancer Ther,2013,12(6):992-1001.
[41] Kim Y,Hammerman PS,Kim J,et al.Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients[J].J Clin Oncol,2014,32(2):121-128.
[42] Chen J,Chen G,Yan Z,et al.TGF-beta1 and FGF2 stimulate the epithelial-mesenchymal transition of HERS cells through a MEK-dependent mechanism[J].J Cell Physiol,2014,229(11):1647-1659.
[43] Trueb B,Amann R,Gerber SD.Role of FGFRL1 and other FGF signaling proteins in early kidney development[J].Cell Mol Life Sci,2013,70(14):2505-2518.
[44] Davies H,Hunter C,Smith R,et al.Somatic mutations of the protein kinase gene family in human lung cancer[J].Cancer Res,2005,65(17):7591-7595.
[45] Roth GJ,Binder R,Colbatzky F,et al.Nintedanib:from discovery to the clinic[J].J Med Chem,2015,58(3):1053-1063.
[46] Shou Y,Hirano T,Gong Y,et al.Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer[J].Br J Cancer,2001,85(11):1706-1712.
[47] Brattstrom D,Bergqvist M,Hesselius P,et al.Elevated preoperative serum levels of angiogenic cytokines correlate to larger primary tumours and poorer survival in non-small cell lung cancer patients[J].Lung Cancer,2002,37(1):57-63.

Progress research on mechanism of FGFR signaling pathway in pathogenesis of IPF and non-small cell lung cancer

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Comments

Recommended 0

[1]	LI Lijing, ZANG Yaru, YU Wenhui, LIANG Junwei, TONG Yanjun. Therapeutic effect of chemotherapy combined with sodium cantharidinate vitamin B6 injection in patientswith non-small cell lung cancer and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2018, 44(06): 1286-1290.
[2]	SUN Hongshuai, ZHU Hua, GAO Haiyan, WAN Guangcai, YU Xiuyan. Value of combined detection of tumor markers SCC-Ag, CEA, CYFRA21-1 and D-dimer in early diagnosis of non-small cell lung cancer [J]. Journal of Jilin University(Medicine Edition), 2018, 44(05): 1020-1024.
[3]	. Research progress in relationships between polymorphisms of DNA damage repair pathway gene and sensitivity and prognosis of non-small cell lung cancer treated with platinum drugs [J]. Journal of Jilin University Medicine Edition, 2018, 44(04): 869-874.
[4]	QUAN Xiaoyue, LIU Bailong, LIU Min, DONG Lihua. Treatment of lung squamous cell carcinoma with apatinib in patient who couldn't tolerate chemotherapy: A case report and literature review [J]. Journal of Jilin University Medicine Edition, 2018, 44(03): 624-627.
[5]	. Research progress in thoracic radiotherapy in limited-disease small cell lung cancer [J]. Journal of Jilin University Medicine Edition, 2018, 44(01): 190-194.
[6]	LIU Xiangliang, JI Wei, LI Li, ZHAO Yinghua, JIA Lin, WANG Zhiqiang, CHEN Xiao, LI Wei. Lung adenocarcinoma treated by Erlotinib HCL Tablets and chemotherapy combined with bevacizumab after drug resistance:A case report and literature review [J]. Journal of Jilin University Medicine Edition, 2017, 43(05): 1019-1024.
[7]	LIU Danqing, YE Shufeng, TONG Weifang, TENG Bo, WANG Sanchun, FENG Qingjie. Renal clear cell carcinoma transferred to nasal cavity and sinuses:A case reportand literature review [J]. Journal of Jilin University Medicine Edition, 2017, 43(04): 829-831.
[8]	. Progress research on effect of long non-coding RNA in occurrence and development of lung cancer [J]. Journal of Jilin University Medicine Edition, 2017, 43(02): 450-453.
[9]	LI Xingxing, TAN Jingjin, JIANG Shan, WAHG Ke. Role of let-7 and HMGA2 in occurrence and development of lung cancer: Meta-analysis [J]. Journal of Jilin University Medicine Edition, 2016, 42(06): 1116-1125.
[10]	XI Yanli, XU Na, LI Shu, WANG Di, WANG Shuran, NIU Fenglan. Inhibitory effect of gallic acid on proliferation of human non-small cell lung cancer A549 cells [J]. Journal of Jilin University Medicine Edition, 2016, 42(06): 1092-1098.
[11]	YUN Fen, JIA Yongfeng, HAN Zhao, SUN Qinnuan, LI Xiuxia, YU Huiling. Expression of HIF-2αin non-small cell lung cancer tissue and its relationships with MVD,Ki67,and GST-π [J]. Journal of Jilin University Medicine Edition, 2016, 42(05): 954-957.
[12]	LIU Huanxin, ZHANG Guoxiang, GUO Linlang, TAN Songshan. Expression of miR-139-5p in small cell lung cancer tissue and its clinical significance [J]. Journal of Jilin University Medicine Edition, 2016, 42(05): 942-948.
[13]	LI Shimeng, PAN Baoxiang, LI Tong, XIE Feng, WANG Hai. Correlation between expression of programmed cell death-ligand 1 protein and prognosis of lung cancer:A Meta-analysis [J]. Journal of Jilin University Medicine Edition, 2015, 41(05): 969-973.
[14]	LIN Xing-yu,YANG Zhi-guang,ZHANG Peng,SHAO Guo-guang. Comparison of curative effects of lobectomy between C-VATS  and thoracotomy in aged patients with lung cancer  [J]. Journal of Jilin University Medicine Edition, 2014, 40(06): 1275-1279.
[15]	ZUO Xiao-jun,NI Guan-ying . Application of 18F-FDG PET-CT in TNM staging of non-small cell lung cancer and clinical significance [J]. Journal of Jilin University Medicine Edition, 2014, 40(06): 1293-1296.